Literature DB >> 7037781

Isolation and characterization of urokinase from human plasma.

T C Wun, W D Schleuning, E Reich.   

Abstract

The presence of activators of the fibrinolytic system in blood plasma has been assumed for a long time but never convincingly documented by the isolation of characterized and physiologically plausible enzymes. The low catalytic efficiency of previously identified plasma plasminogen activators, which has made their physiological significance uncertain, prompted us to search for other plasma enzymes, resembling especially the potent urinary activator, urokinase. We report here the detection of a urokinase-like activity in human plasma, and the isolation of the enzyme from whole plasma protein fractions. The purified enzyme is indistinguishable from the 53,000-dalton components of human urinary urokinase in the following respects: apparent Mr on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, double immunodiffusion, amino acid analysis, two-dimensional tryptic peptide maps, catalytic efficiency with synthetic peptide substrates, and inhibitor spectrum. The results suggest (a) that the enzyme is present in plasma in a latent form whose nature remains to be defined, and (b) that the circulating concentration is at least 5 to 10 microgram/liter, and sufficient to generate substantial levels of plasmin, particularly if activation were somehow confined by localization at specific sites.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7037781

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

2.  Identification of a plasminogen activator derived from nasopharyngeal carcinoma.

Authors:  T Kosugi; G W Huang; M Nakamura; S Koja; H T Nong
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

3.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.

Authors:  M P Stoppelli; A Corti; A Soffientini; G Cassani; F Blasi; R K Assoian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

4.  Binding of tissue plasminogen activator to human aortic endothelial cells.

Authors:  M A Sanzo; S C Howard; A J Wittwer; H M Cochrane
Journal:  Biochem J       Date:  1990-07-15       Impact factor: 3.857

5.  Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.

Authors:  D F Alonso; E F Farías; V Ladeda; L Davel; L Puricelli; E Bal de Kier Joffé
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.

Authors:  S Thorsen; S Müllertz; E Suenson; P Kok
Journal:  Biochem J       Date:  1984-10-01       Impact factor: 3.857

Review 7.  Natural anticoagulant mechanisms.

Authors:  R D Rosenberg; J S Rosenberg
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

8.  Fibrinolytic activity in renal venous blood in man.

Authors:  J Schrader; K L Neuhaus; U Tebbe; H Köstering; F Scheler
Journal:  Klin Wochenschr       Date:  1986-07-01

9.  Isolation and identification of an endophytic strain EJS-3 producing novel fibrinolytic enzymes.

Authors:  Fengxia Lu; Lijun Sun; Zhaoxin Lu; Xiaomei Bie; Yaowei Fang; Shu Liu
Journal:  Curr Microbiol       Date:  2007-05-08       Impact factor: 2.188

10.  Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.

Authors:  E G Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.